Best Blood cancer treatment Hospitals in Istanbul, 21 Results

The blood cancer survival rate in India has significantly increased over the past ten years. While the survival rate depends completely on early detection and timely treatment, the 5-year survival rate in India varies between 60-90%, depending on treatment protocol chosen, stage of cancer, age and other comorbidities of the patient. Further, according to MedicoExperts, for those who have undergone BMT, the survival rate is more than 75%. 

Because there was so little study on leukemia and other forms of blood cancer even twenty years ago, hearing the words "you have leukemia" meant a death sentence. As a result, therapeutic choices were restricted and sometimes unsuccessful. 

Even after hearing those words, you will live and enjoy a healthy and productive life in the twenty-first century, owing to better detection procedures, greater information and research on blood cancer in general, and better and more successful treatment programs.

Blood cancer has an extremely high cure rate. You can expect to be effectively treated if you are diagnosed early.

Leukemia is a kind of blood cancer that is caused by a genetic mutation. A genetic mutation doesn't cause other types of blood cancer.

Knowing what side effects may occur, how much work you may miss, and what long-term repercussions will help you better deal with it, reducing stress.

There are three major types of cancer that affect the blood are:

• Leukaemia: People suffering from leukaemia make a lot of white blood cells that cannot fight infections. It is further divided into four types depending on the kind of white blood cells affected and whether they multiply (acute) or grow slowly (chronic).
   
• Lymphoma: This cancer develops in the lymph system and has two main categories.
• Hodgkin's lymphoma
• Non-Hodgkin's lymphoma
   
• Myeloma: This originates in the plasma cells in the bone marrow. The plasma cells make antibodies in the body. Myeloma spreads through the bone marrow and can damage bones.